Market Watch (Free subscription) | 26/08/2008
Drug stocks moved higher in early trading Tuesday as shares of partners Elan Corp. and Biogen Idec rose moderately the day after U.S. regulators said they were updating the labeling of their drug Tysabri to reflect renewed safety concerns.
Market Watch (Free subscription) | 26/08/2008
BOSTON (MarketWatch) -- Drug stocks moved higher in early trading Tuesday as shares of partners Elan Corp. and Biogen Idec rose moderately the day after U.S. regulators said they were updating the labeling of their drug Tysabri to reflect renewed safety concerns. The Amex Pharmaceutical Index was up nominally at 309.9 and the Amex Biotechnology Index advanced 0.4% to 844.1. Biogen shares edged up...
Reuters UK (Free subscription) | 25/08/2008
WASHINGTON (Reuters) - Prescribing instructions for Biogen Idec and Elan Corp's drug Tysabri should be revised to note cases of a serious brain disorder in patients who were using it as their sole treatment for multiple sclerosis, U.S. health regulators said on Monday.
Reuters UK (Free subscription) | 24/08/2008
DUBLIN (Reuters) - Private equity firm Warburg Pincus is set to enter the race to acquire the drug delivery unit of Ireland's Elan Corp , the Sunday Times newspaper reported.
EmailWire.Com (Free subscription) | 18/08/2008
(EMAILWIRE.COM, August 18, 2008 ) DALLAS, Texas - Today's Trade Alerts include: Elan Corp. plc (NYSE: ELN), Pfizer Inc. (NYSE: PFE), Amgen Inc. (Nasdaq: AMGN), Genentech Inc. (NYSE: DNA), Biogen Idec Inc. (Nasdaq: BIIB), and Gilead Sciences Inc. (Nasdaq: GILD). Elan Corp. plc (ELN) shares...
Market Watch (Free subscription) | 15/08/2008
Drug stocks gain in early action Friday as shares of Elan Corp. continue their slow rebound after being battered earlier this month by negative drug news.
Market Watch (Free subscription) | 15/08/2008
BOSTON (MarketWatch) -- Drug stocks gained in early action Friday as shares of Elan Corp. continued to slowly rebound after being battered late last month by negative drug news. The Amex Pharmaceutical Index and the Amex Biotechnology Index were both up about 0.5% at 317.2 and 892.0, respectively. Elan shares climbed 5% to $12.35. Market Pulse Stories are Rapid-fire, short news bursts on stocks and...
Market Watch (Free subscription) | 14/08/2008
BOSTON (MarketWatch) -- Drug stocks slipped in early action Thursday during a relatively placid morning for the pharmaceutical and biotechnology sectors on Wall Street. The Amex Pharmaceutical Index eased 0.4% to 313.0 and the Amex Biotechnology Index inched down 0.2% to 869.2. Elan Corp. shares were the notable movers, up 2% at $11.11. Market Pulse Stories are Rapid-fire, short news bursts on stocks...
Market Watch (Free subscription) | 05/08/2008
BOSTON (MarketWatch) -- Drug stocks climbed into positive territory early Tuesday as shares of Elan Corp. gained after analysts at Canaccord upgraded the stock to hold from sell. The Amex Pharmaceutical Index rose 0.9% to 310.4 and the Amex Biotechnology Index advanced 0.8% to 843.9. Elan shares were up 5% at $11.59. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they...
Fox News (Free subscription) | 04/08/2008
Cambridge-based Biogen Idec Inc. and Ireland-based Elan Corp. defended their multiple sclerosis drug Tysabri after reporting two new cases of a potentially fatal side effect, saying the treatment is still worth the risk to patients.
NewsObserver.com - Business (Free subscription) | 02/08/2008
Biogen Idec Inc. and Elan Corp. defended their multiple sclerosis drug Tysabri on Friday after reporting two new cases of a potentially fatal side effect, saying the treatment is still worth the risk to patients.
New York Times (Free subscription) | 01/08/2008
Biogen Idec Inc. and Elan Corp. defended Tysabri on Friday, saying the treatment is still worth the risk to patients.
Market Watch (Free subscription) | 01/08/2008
A July 31 article reported an incorrect number of past patient deaths from the multiple-sclerosis drug Tysabri, sold by Biogen Idec Inc. and Elan Corp. Tysabri was actually linked to two deaths.
The Earth Times Online Newspaper (Free subscription) | 01/08/2008
DUBLIN/LONDON (Reuters) - Shares in Irish drugmaker Elan Corp PLC lost half their value on Friday while partner Biogen Idec tumbled 25 percent as renewed safety concerns call into question the future of their multiple sclerosis drug Tysabri.
MarketBeat (Free subscription) | 01/08/2008
Suffice to say that weeks don’t get much worse than the one experienced by Elan Corp. PLC. The Irish drugmaker was battered early in the week by lackluster results from its Bapineuzumab treatment for Alzheimer’s disease. Friday, shares are being dumped after the company said two more cases of the brain disorder progressive multifocal leukoencephalopathy, [...]
